3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Completed
9
Terminated
8
Recruiting
2
Active not recruiting
2
Unknown
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
Lymphoid
1
Head & Neck
1
CNS
1
Conditions
Melanoma
8
Leukemia, Myeloid, Acute
6
Breast Neoplasms
6
Colorectal Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Ovarian Neoplasms
4
Neoplasm Metastasis
4
Triple Negative Breast Neoplasms
3
Skin Neoplasms
3
Mesothelioma, Malignant
3
Lymphoma, Non-Hodgkin
3
Uveal Melanoma
2
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Sarcoma
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion, Malignant
2
Neuroblastoma
2
Neoplasms
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid
2
Leukemia
2
Head and Neck Neoplasms
2
Glioblastoma
2
Esophageal Neoplasms
2
Carcinoma, Merkel Cell
2
Urinary Bladder Neoplasms
1
Turcot syndrome
1
Interventions
pembrolizumab
38
Blood Specimen Collection
38
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
17
Exercise
17
Carboplatin
17
Nivolumab
15
atezolizumab
14
Paclitaxel
14
Cisplatin
14
Drug Therapy
13
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
11
Trastuzumab
10
Pemetrexed
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
Interleukin-2
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled
NCT05086692
2025-07-09
ABILITY-1
Medicenna Therapeutics, Inc.
Phase 1/2
Recruiting
115 enrolled